Study the Anticancer Properties of Thymol-Loaded PEGylated Bovine Serum Albumin Nanoparticles Conjugated with Folic Acid.
antioxidant
cancer therapy
folic acid
nanoparticles surface-modified
thymol
Journal
Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
31
07
2023
accepted:
11
10
2023
medline:
29
11
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
Phenolic compounds such as Thymol have an effective role in suppressing cancer, however, their low solubility in aqueous solution has limited their use. This study aimed to prepare Thymol (TY)-loaded bovine serum albumin (BSA) nanoparticles surface-modified with polyethylene glycol (PEG) conjugated with folic acid (FA) and evaluate their inhibitory activity on cancer cells. The TY-BSA-PEG-FA was characterized using DLS, FESEM, and FTIR. The encapsulation efficiency (EE) was evaluated indirectly by using UV absorption. The antioxidant property of nanoparticles was evaluated by 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH), and ferric reducing ability of plasm (FRAP) methods. The effects of nanoparticles against cancer cells were investigated by MTT, AO/PI, flow cytometry, and real-time qPCR methods. The results showed the spherical morphology of TY-BSA-PEG-FA with an average size of 70.0 nm, a PDI of 0.32, a zeta potential of -11.3 mV, and an EE of 89.0±2.3 %. The cytotoxicity effects of nanoparticles against all cell lines were in a concentration-dependent manner. AGS gastric cancer cells were reported to be the most vulnerable to treatment, while pancreatic cancer cells (PANC-1) and normal skin cells (HFF) would be the most resistant. The SubG1 phase arrest of about 66 % occurred at 85 μg/mL. An increase in apoptotic cells in fluorescent staining, along with decreased expression of Bcl-2 and increased expression of the BAX gene demonstrated the induction of apoptosis in treated cells. The powerful inhibitory effect of nanoparticles in inhibiting ABTS free radicals (IC
Identifiants
pubmed: 37823866
doi: 10.1002/cbdv.202301122
doi:
Substances chimiques
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid
28752-68-3
Serum Albumin, Bovine
27432CM55Q
Thymol
3J50XA376E
Folic Acid
935E97BOY8
Polyethylene Glycols
3WJQ0SDW1A
Free Radicals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202301122Informations de copyright
© 2023 Wiley-VHCA AG, Zurich, Switzerland.
Références
D. S. Shewach, R. D. Kuchta, Chem. Rev. 2009, 109, 2859-2861.
R. Visconti, D. Grieco, Curr. Opin. Drug Discovery Dev. 2009, 12, 240-245.
S. Reuter, S. C. Gupta, M. M. Chaturvedi, B. B. Aggarwal, Free Radical Biol. Med. 2010, 49, 1603-1616.
L. Zhu, M. Luo, Y. Zhang, F. Fang, M. Li, F. An, D. Zhao, J. Zhang, Coord. Chem. Rev. 2023, 475, 214875.
V. Fuchs-Tarlovsky, Nutrition 2013, 29, 15-21.
C. B. Simone II, N. L. Simone, V. Simone, C. B. Simone, Altern Ther Health Med. 2007, 13, 40-47.
G. Briguglio, C. Costa, M. Pollicino, F. Giambo, S. Catania, C. Fenga, Int. j. funct. nutr. 2020, 1, 1-1.
H. R. Seresht, B. J. Albadry, A. K. M. Al-mosawi, O. Gholami, H. Cheshomi, Pharm. Chem. J. 2019, 53, 101-107;
M. Karimi, F. Gheybi, P. Zamani, M. Mashreghi, S. Golmohammadzadeh, S. A. Darban, A. Badiee, M. R. Jaafari, Int. J. Pharm. 2020, 580, 119211.
D. D. Deb, G. Parimala, S. S. Devi, T. Chakraborty, Chem.-Biol. Interact. 2011, 193, 97-106.
O. Abazari, A. Divsalar, R. Ghobadi, J. Biomol. Struct. Dyn. 2020, 38, 609-615;
M. T. Islam, A. B. Khalipha, R. Bagchi, M. Mondal, S. Z. Smrity, S. J. Uddin, J. A. Shilpi, R. Rouf, IUBMB Life 2019, 71, 9-19.
M. F. Nagoor Meeran, H. Javed, H. Al Taee, S. Azimullah, S. K. Ojha, Front. Pharmacol. 2017, 8, 380.
X. Li, T. He, X. Wang, M. Shen, X. Yan, S. Fan, L. Wang, X. Wang, X. Xu, H. Sui, Chem. Biodiversity 2019, 16, e1900254.
F.-p. Chen, N.-q. Kong, L. Wang, Z. Luo, J. Yin, Y. Chen, Food Chem. 2021, 334, 127594.
J. K. Patra, G. Das, L. F. Fraceto, E. V. R. Campos, M. d. P. Rodriguez-Torres, L. S. Acosta-Torres, L. A. Diaz-Torres, R. Grillo, M. K. Swamy, S. Sharma, J. Nanobiotechnol. 2018, 16, 1-33.
M. S. Arayne, N. Sultana, F. Qureshi, Pak. J. Pharm. Sci. 2007, 20, 340-348;
R. R. Joseph, S. S. Venkatraman, Nanomedicine 2017, 12, 683-702;
K. Shakerimanesh, F. Bayat, A. Shahrokhi, A. Baradaran, E. Yousefi, M. Mashreghi, A. Es-Haghi, M. E. T. Yazdi, Mater. Technol. 2022, 37, 2853-2860.
R. Solanki, H. Rostamabadi, S. Patel, S. M. Jafari, Int. J. Biol. Macromol. 2021, 193, 528-540.
A. Abuchowski, J. R. McCoy, N. C. Palczuk, T. van Es, F. F. Davis, J. Biol. Chem. 1977, 252, 3582-3586.
J. S. Suk, Q. Xu, N. Kim, J. Hanes, L. M. Ensign, Adv. Drug Delivery Rev. 2016, 99, 28-51.
V. Weissig, T. K. Pettinger, N. Murdock, Int. J. Nanomed. 2014, 9, 4357.
P. Ebrahimnejad, A. S. Taleghani, K. Asare-Addo, A. Nokhodchi, Drug Discovery Today 2022, 27, 471-489;
M. Mashreghi, M. R. Jaafari, in Functional Lipid Nanosystems in Cancer, Jenny Stanford Publishing, 2021, pp. 429-448;
M. Mashreghi, P. Zamani, M. Karimi, A. Mehrabian, M. Arabsalmani, J. Zarqi, S. A. Moosavian, M. R. Jaafari, Biotechnol. Prog. 2021, 37, e3116;
N. Wathoni, L. E. Puluhulawa, I. M. Joni, M. Muchtaridi, A. F. A. Mohammed, K. M. Elamin, T. Milanda, D. Gozali, Drug Delivery 2022, 29, 2959-2970.
A. K. Jangid, S. Kim, K. Kim, Biomater. Res. 2023, 27, 1-29.
M. Fernández, F. Javaid, V. Chudasama, Chem. Sci. 2018, 9, 790-810.
C. Folle, A. M. Marqués, N. Díaz-Garrido, M. Espina, E. Sánchez-López, J. Badia, L. Baldoma, A. C. Calpena, M. L. García, J. Nanobiotechnol. 2021, 19, 1-21.
F. M. Veronese, G. Pasut, Drug Discovery Today 2005, 10, 1451-1458.
R. Ridolfo, D. S. Williams, J. C. van Hest, Polym. Chem. 2020, 11, 2775-2780.
M. A. Subhan, S. S. K. Yalamarty, N. Filipczak, F. Parveen, V. P. Torchilin, J. Pers. Med. 2021, 11, 571.
P. Shi, Z. Cheng, K. Zhao, Y. Chen, A. Zhang, W. Gan, Y. Zhang, J. Nanobiotechnol. 2023, 21, 1-27;
M. F. Attia, N. Anton, J. Wallyn, Z. Omran, T. F. Vandamme, J. Pharm. Pharmacol. 2019, 71, 1185-1198.
L. Qi, Y. Guo, J. Luan, D. Zhang, Z. Zhao, Y. Luan, J. Mater. Chem. B 2014, 2, 8361-8371.
E. S. Lee, K. Na, Y. H. Bae, J. Controlled Release 2003, 91, 103-113;
F. Wang, D. Zhang, Q. Zhang, Y. Chen, D. Zheng, L. Hao, C. Duan, L. Jia, G. Liu, Y. Liu, Biomaterials 2011, 32, 9444-9456.
A. Retnakumari, S. Setua, D. Menon, P. Ravindran, H. Muhammed, T. Pradeep, S. Nair, M. Koyakutty, Nanotechnology 2009, 21, 055103.
S. Muralidharan, K. Shanmugam, J. Pharm. Innov. 2021, 16, 269-278.
S. George, H. Abrahamse, Antioxidants 2020, 9, 1156;
F. Ciccarese, V. Raimondi, E. Sharova, M. Silic-Benussi, V. Ciminale, Antioxidants 2020, 9, 211.
H. Cao, X. Chen, K. Yamamoto, Anti-Cancer Agents Med. Chem. 2012, 12, 940-948.
R. C. Pedrozo, E. Antônio, N. M. Khalil, R. M. Mainardes, Braz. J. Pharm. Sci. 2020, 56.
L. Martínez-Jothar, N. Beztsinna, C. F. van Nostrum, W. E. Hennink, S. Oliveira, Mol. Pharm. 2019, 16, 1633-1647.
H. L. Li, Y. X. He, Q. H. Gao, G. Z. Wu, Mol. Med. Rep. 2014, 9, 786-792.
Y. Dong, R. Fu, J. Yang, P. Ma, L. Liang, Y. Mi, D. Fan, Int. J. Nanomed. 2019, 14, 6971-6988.
F. Liu, M. Lan, B. Ren, L. Li, T. Zou, Z. Kong, D. Fan, T. Cai, Y. Cai, Cancer Nanotechnol. 2022, 13, 2.
P. Berraondo, M. F. Sanmamed, M. C. Ochoa, I. Etxeberria, M. A. Aznar, J. L. Pérez-Gracia, M. E. Rodríguez-Ruiz, M. Ponz-Sarvise, E. Castañón, I. Melero, Br. J. Cancer 2019, 120, 6-15.